| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b15919faeefa7b546850ad858623c4e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_163a286bfd725895360e88153eaa6c21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f287069cece8817f7836eeef5c1058dd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd40c8dbc780eafc950615b41b49c4ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2105b9682ef875ab2d232684e85f8260
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3dfdf26a4b85e8f8db7ef9399141752c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-33 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-31 |
| filingDate |
2002-02-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de73783b00f104f2727802e9c07624df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c658ac5d160d630f5506acfe301c216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae78da39e05f41214e5234f04cbc6e5c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cfb53eb8fe26024ebc313247e735e0b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36072deba5fac90a5ee013cfc9145fb6 |
| publicationDate |
2002-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-02062379-A2 |
| titleOfInvention |
Clostridium difficile vaccine |
| abstract |
A vaccine for the treatment or prophylaxis of C. difficile associated disease comprises a C. difficile gene or a C. difficile peptide/polypeptide or a derivative or fragment or mutant or variant thereof which is immunogenic in humans. The gene encodes a C. difficile surface layer protein, SlpA or variant or homologue thereof. The peptide/polypeptide is a C. difficile surface layer protein, SlpA or variant or homologue thereof. The vaccine may comprise a chimeric nucleic acid sequence. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2261253-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006003426-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7608265-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023099711-A2 |
| priorityDate |
2001-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |